多态结构确定宏循环药物帕里塔普雷维尔的MicroED
Guanhong Bu1, Emma Danelius1,2, Lianne H E Wieske3
1Department of Biological Chemistry, University of California Los Angeles, 615 Charles E. Young Drive South, Los Angeles, CA, 90095, USA.
Advanced biology
|February 21, 2024
概括
微晶电子衍射揭示了C型肝炎病毒药物paritaprevir的两个晶体形式. 这些独特的结构显示出形状变化,有助于优化药物与HCV蛋白酶标的结合.
科学领域:
- 结构生物学是结构生物学.
- 药物发现 药物发现
- 晶体学 晶体学是指结晶学.
背景情况:
- 帕里塔普雷维尔是一种口服生物可用的宏环药物,用于慢性型肝炎病毒 (HCV) 感染.
- 帕里塔普雷维尔的精确结构一直很难确定,直到最近的进展.
研究的目的:
- 使用MicroED阐明帕里塔普雷维尔独特的多态晶体结构.
- 研究这些多态体内的构造变异及其对药物向相互作用的影响.
主要方法:
- 微晶电子衍射 (MicroED) 用于解决两个不同的帕里塔普雷维尔多态的结构.
- 进行了分子对接模拟,以评估帕里塔普雷维尔构成与HCV NS3/4A血清蛋白酶的结合.
主要成果:
- 从一个单一的实验中,成功地解决了帕里塔普雷维尔的两个不同的多态晶体形式.
- 在不同多态体的宏循环核心和替代物中观察到形状变化.
- 分子对接表明,在HCVNS3/4A血清蛋白酶的活性位点内,一种帕里塔普雷维尔构造具有有利的结合,涉及性和键相互作用.
结论:
- 该研究证明了MicroED在从相同的实验设置中导出多重多态和宏循环构造中的实用性.
- 获得的结构见解可以为优化针对HCVNS3/4A血清蛋白酶的乙硫胺胺抑制剂提供信息.
- 了解这些结构变异对于开发更有效的C型肝炎治疗方法至关重要.
相关概念视频
¹³C NMR: Distortionless Enhancement by Polarization Transfer (DEPT)
When proton-coupled carbon-13 spectra are simplified by a broadband proton decoupling technique, structural information about the coupled protons is lost. Distortionless enhancement by polarization transfer (DEPT) is a technique that provides information on the number of hydrogens attached to each carbon in a molecule. While the DEPT experiment utilizes complex pulse sequences, the pulse delay and flip angle are specifically manipulated. The resulting signals have different phases depending on...
Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Pharmacodynamic Models: Linear Concentration–Effect Model
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


